Clinical Trial Update: Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 safety and efficacy trial of danazol in patients with Fanconi anemia or Dyskeratosis Congenita was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskeratosis Congenita
• Fanconi Anemia

Drugs mentioned

• Danazol (danazol)

Snippet

Sponsor: Boston Children's Hospital | Conditions: Fanconi Anemia, Dyskeratosis Congenita | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-02-19